Information About Ketek
Ketek (telithromycin) was approved by the European Commission in July 2001 and subsequently came on sale
in October 2001. In USA, telithromycin gained FDA approval April 1, 2004.
Telithromycin prevents bacteria from growing, by interfering with their protein synthesis.
Ketek (telithromycin) is acid-stable and can be taken orally without being damaged by gastric acids. It is rather
rapidly absorbed. Due to the high concentration in phagocytes (white blood cells), telithromycin is actively
transported to the site of infection. During active phagocytosis, large concentrations of telithromycin is released.
The concentration of telithromycin in the tissues is much higher than in the blood.
Ketek is mainly metabolized in the liver (the organ which it may damage), with the main elimination route
being the bile. A small portion is also excreted into the urine. Telithromycin's half-life is approximately 10 hours.
The most common side effects are diarrhea, nausea, abdominal pain and vomiting. Headache and odd taste
sensations also occur. Less common side-effects include palpitations, blurred vision and rashes.
Rare, but severe side effects reported in January 2006 involve damage to the liver. Three different incidents
have been reported: one ending in death, one in a liver transplant and one case of drug-induced hepatitis.
These side effects are the subject of class-actions.
Ketek has been known to cause false positive readings in drug screenings for cocaine and amphetamines.
Above information is from Wikipedia and other sources. All trademarks belong to their owners.
Check this site for latest information on class-action lawsuits filed on behalf of victims of
Ketek liver damage.
Conclusion